Psylo

Thank you for celebrating an incredible year with us! We’re immensely grateful to everyone who joined Psylo’s end-of-year celebration last night. Your support and collaboration have made this a truly fantastic year. A special thanks to our amazing investors, including Tenmile, Main Sequence, UNSW Founders and M8 Ventures, whose belief in our vision continues to drive us forward. Here’s to an even bigger and brighter 2025! 🌟 (More amazing and professional photos from the evening to come!)

There are many nuances regarding the structural neural plasticity associated with antidepressant drugs. 💊🧠   We share our thoughts here in a Nature Reviews Neuroscience article, led by Clara Liao and included co-authors from Conor Liston’s lab. We begin by critically reviewing the human data suggesting abnormalities of excitatory synapses in depression, focusing on the prefrontal cortex. And I mean critically… there are many correlates, but caveats abound. We then pivot to novel optical imaging methods that can determine the in vivo turnover dynamics of dendritic spines, which has provided new insights into antidepressant drug action. There is a common refrain that “many drugs can alter structural neural plasticity”. We extracted data from published imaging studies on various drugs to show that the drugs are not all the same and the structural remodeling differs in effects and time courses. We consider what this may mean in terms of the biology – timing and dose? Wiring or synaptic weight change? Formation versus persistent integration? Interaction with prior experience like stress?   I believe there are the translational opportunities in terms of using structural neural plasticity for preclinical drug development. Finally, I am excited about the promise for reverse translation for other antidepressant interventions, for example accelerated TMS which may leverage similar plasticity mechanisms. A view-only link for full-text access: https://rdcu.be/d0Cbz Meinig School of Biomedical Engineering at Cornell University, Cornell Engineering, Weill Cornell Medicine, Nature Portfolio   https://lnkd.in/emYZ33s8

Did you know that #neurological disorders are now the leading cause of disability worldwide? While #MentalHealth conditions contribute nearly 5% to the global disease burden. Our October newsletter explores the disease burden and highlights the large #TreatmentGap for these conditions, especially in low-income countries where up to 96% of affected individuals go untreated. Could neuroplasticity-promoting therapies, like #neuroplastogens, offer new hope for treating depression and neurodegenerative diseases? 🧠 Our newsletter also features research highlights, including: - Antidepressant discontinuation and psilocybin efficacy - Psilocybin-assisted neurofeedback treatment - Study design and its impact on psychedelic efficacy outcomes - Psychedelics in autistic adults - BDNF as a predictor of antidepressant response - The role of serotonin receptors in disease mechanisms 🥼 Plus, new clinical trials exploring psilocybin for ALS and cognitive control in seizure disorders, and the use of THC as an active placebo! 👉👉Explore these topics and more in our latest newsletter: https://lnkd.in/gEe-fJ8i Subscribe today to stay on the cutting edge of neuroscience research and clinical advancements.

💜 WE VISITED Psylo💜 ....and they have some very exciting news! 👀 Last week, co-founder of Psylo, 🧪 Joshua Ismin welcomed the team and community into the Psylo labs at UNSW! 🎉 🎊 More importantly... Psylo made an announcement at the end of last week: "We’re excited to share that Psylo, Tessara Therapeutics, and the Brain and Mind Centre, University of Sydney have been awarded a $3 million CRC-P grant to develop novel neuroplastogens for the treatment of substance use disorders!" Check out the full post here 👉🤠 https://loom.ly/qF5_5gI

We’re excited to share that Psylo, Tessara Therapeutics, and the Brain and Mind Centre, University of Sydney have been awarded a $3 million CRC-P grant to develop novel neuroplastogens for the treatment of substance use disorders! Together, we're accelerating the development of neuroplastogens, with a focus on methamphetamine addiction. This collaboration will leverage Psylo’s pioneering neuroplastogens, Tessara’s novel microtissue technology and the University of Sydney’s neuroscience expertise to address addiction and mental health challenges. We’re grateful for the support of the Australian Government and excited to join forces to develop innovative, brain-rewiring therapies that offer new hope for those struggling with addiction. 👉 Read more about this exciting project here: https://lnkd.in/gGjWkE_s 🧪 Joshua Ismin 💊 Sam Banister Nick Everett ⚗️ William Jorgensen Jin Tan Joanna Hare Lachlan Whish Mario de la Fuente, PharmD, PhD Dilara Bahceci Krista Licata Christos Papadimitriou Paul Adlard Alan Kozikowski Alex Kwan Graham Pechenik Dr. Jianmin Duan Anna Goldys Ryan Bethencourt Ian Torrance Eric J. Nestler, MD, PhD John Krystal Donald Gehlert, Ph.D. Forest Heims Main Sequence Tenmile Lionheart Ventures Focalpoint Partners Negev Capital Possible Ventures Startmate UNSW Founders Radar Ventures

The Psylo team had a fantastic day connecting with Scott Thompson and his team at the University of Colorado Anschutz Medical Campus to learn about the important research they’re leading on depression mechanisms and the action of antidepressants and psychedelics, right here in Colorado. We're thrilled to be part of this incredible ecosystem and look forward to contributing to the incredible research happening in our state! Devin Effinger, PhD, Joselyn Calderon, Jillian King, 💊 Sam Banister, Krista Licata, Dilara Bahceci, University of Colorado Boulder

In Psylo's latest Neuroscience Newsletter: New findings in anxiety, depression and addiction, brain connectivity, predicting efficacy, sex differences, neuroplasticity, new tools, and exploring molecular targets of psychedelics beyond 5-HT2A. 👉https://lnkd.in/g7SN7xw5

Check out how Psylo (Startmate, W21) and Enosis Therapeutics are using tech to tackle medicinal psychedelics 🦠 "Psylo has taken a different approach to psychedelic therapy by developing synthetic compounds inspired by psychedelics. Unlike psilocybin or MDMA, these compounds are designed to remove the hallucinogenic properties, offering patients the therapeutic benefits without the need for intense, supervised psychedelic experiences. 🧪 Joshua Ismin, co-founder and CEO of Psylo, explained the company is focused on creating novel compounds — known as neuroplastogens — which work on the same receptors as traditional psychedelics, but don’t induce hallucinations." Read more here!! https://lnkd.in/gz-DkJQE

I am delighted to be speaking at the 7th Neuropsychiatric Drug Development Summit in Boston next week! I will speak on the panel, "Navigating the Commercial Challenges of Reimbursement & Market Access to Streamline Route to Market for Psychiatric Therapeutics." I’ll be speaking alongside Dina Burkitbayeva (Freedom Biosciences), Charmaine Lykins (MapLight Therapeutics, Inc.) and Elemer Piros (Rodman & Renshaw), where we’ll address crucial questions such as: - How can we effectively commercialize neuropsychiatric products and secure payer support? - What strategies can help lower human resource costs to boost profitability? - How do we identify the most valuable areas for commercial investment in psychiatry? I'm looking forward to engaging with industry leaders and contributing to the future of psychiatric therapeutics. 🗓 September 26th at 4:00 PM 🤝 If you're attending, let’s connect! Registration link here: https://ter.li/0c7c90 World CNS Series Ellie Rapps The George Institute for Global Health Psylo

Psylo and Enosis: Advancing neuropsychiatric treatment with innovative technologies We're proud to be featured in SmartCompany alongside Enosis Therapeutics for our efforts to revolutionize neuropsychiatric treatment. While Enosis is harnessing virtual reality (VR) to enhance therapy, Psylo is at the forefront of drug discovery, developing novel neuroplastogens that provide the therapeutic benefits of psychedelics without inducing hallucinations. As Australia becomes a global test case for psychedelic-assisted therapies, we’re focused on making treatments more accessible, scalable, and effective. Our compounds target the same receptors as traditional psychedelics but with fewer side effects and faster action than current antidepressants. Read the full article, or reach out, to discover how we're shaping the future of neuropsychiatric treatments. https://lnkd.in/gz-DkJQE #Psylo #Biotech #MentalHealth #Neuropsychiatry 🧪 Joshua Ismin 💊 Sam Banister Dr Prash P. Agnieszka Sekula